Influence of different chelators (HYNIC, MAG3 and DTPA) on tumor cell accumulation and mouse biodistribution of technetium-99m labeled to antisense DNA

Abstract. We have shown recently that cell accumulation in culture of antisense DNA is strongly influenced by the presence of a 99mTc-MAG3 group for radiolabeling. We have now compared the in vitro and mouse in vivo behavior of 99mTc when radiolabeled to one antisense phosphorothioate DNA by three different methods. The 18-mer antisense DNA against the RIα subunit of PKA was conjugated via a primary amine on the 5'-end with the NHS esters of HYNIC and MAG3 and by the cyclic anhydride of DTPA. Surface plasmon resonance measurements revealed that the association rate constant for hybridization was unchanged for all three chelators as compared with that of the native DNA. Size exclusion HPLC showed rapid and quantitative protein binding for all three chelators upon incubation of labeled DNAs in 37°C serum and cell culture medium. However, in each case, radiolabeled and intact oligonucleotide was still detectable after 24 h. Cellular uptake was tested in an RIα mRNA-positive cancer cell line. The order of cellular accumulation of 99mTc was DTPA>HYNIC(tricine)>MAG3, with the differences increasing with time between 4 and 24 h. The rate of 99mTc egress from cells was found to be MAG3>HYNIC>DTPA, which may explain the order of cellular accumulation. The biodistribution in normal mice was heavily influenced by the labeling method and followed a pattern similar to that seen previously by us for peptides labeled with the same chelators. In conclusion, although these studies concerned only one antisense DNA in one cell line, the results suggest that the success of antisense imaging may depend, in part, on the method of radiolabeling.

[1]  M. Rusckowski,et al.  Technetium-99m antibodies labeled with MAG3 and SHNH: an in vitro and animal in vivo comparison. , 1996, Nuclear medicine and biology.

[2]  D. Hnatowich Antisense and nuclear medicine. , 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[3]  Bernard Bendriem,et al.  In vivo imaging of oligonucleotides with positron emission tomography , 1998, Nature Medicine.

[4]  R. Karlsson,et al.  Real-time biospecific interaction analysis using surface plasmon resonance and a sensor chip technology. , 1991, BioTechniques.

[5]  C. Cantor,et al.  Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in mice. , 1996, The Journal of pharmacology and experimental therapeutics.

[6]  M. Rusckowski,et al.  Different chelators and different peptides together influence the in vitro and mouse in vivo properties of 99Tcm , 2001, Nuclear medicine communications.

[7]  R. L. Childs,et al.  Optimum conditions for labeling of DTPA-coupled antibodies with technetium-99m. , 1985, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[8]  R. Wagner Gene inhibition using antisense oligodeoxynucleotides , 1994, Nature.

[9]  V. Vlassov,et al.  Mechanism of oligonucleotide uptake by cells: involvement of specific receptors? , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[10]  G. Sfakianakis,et al.  Noninvasive imaging of c-myc oncogene messenger RNA with indium-111-antisense probes in a mammary tumor-bearing mouse model. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[11]  R. L. Childs,et al.  Radioactive labeling of antibody: a simple and efficient method. , 1983, Science.

[12]  S. Crooke,et al.  Molecular mechanisms of antisense drugs: RNase H. , 1998, Antisense & nucleic acid drug development.

[13]  D. Hnatowich Changing focus: applying antisense to nuclear medicine imaging. , 1999, Molecular medicine today.

[14]  Magnus Malmqvist,et al.  Biospecific interaction analysis using biosensor technology , 1993, Nature.

[15]  S. Crooke Progress toward oligonucleotide therapeutics: pharmacodynamic properties , 1993, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[16]  A. Fischman,et al.  Technetium-99m-human polyclonal IgG radiolabeled via the hydrazino nicotinamide derivative for imaging focal sites of infection in rats. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[17]  P. Winnard,et al.  Can a cysteine challenge assay predict the in vivo behavior of 99mTc-labeled antibodies? , 1994, Nuclear medicine and biology.